Despite an influx of data breach class actions and a large number of competing proceedings, the past financial year has seen the lowest number of new class actions filed in six years, according to a new report.
A judge has approved the settlement of a class action brought on behalf of sovereign bondholders over the disclosure of climate change risks, despite a late scrap with the government over whether the deal puts a stop to future cases.
An Australian law firm is investigating a class action against drug manufacturers over a commonly prescribed antibiotic said to cause “disabling” side effects, including nerve damage and psychosis.
A nose job patient who allegedly defamed his surgeon has been hit with indemnity costs after refusing the surgeon’s “exceptionally generous” offer to settle.
A judge has dismissed a Paralympian cyclist’s defamation suit over a Facebook comment by a former girlfriend, finding he suffered no serious harm from the comment, which accused him of lying about his disability.
The ACCC has approved the buyout of Australian energy giant Origin Energy, after finding that significant competition concerns were outweighed by the likely benefits to the country’s transition to renewable energy.
A bondholder class action against Virgin is heating up, with the airline filing a cross-claim seeking the court’s approval to demand periodic payments from the applicant to cover its costs under a contentious indemnity clause.
The Commonwealth of Australia has asked the court to throw out an adverse action suit brought by a former political staffer who says she was subjected to “a course of bullying behaviour” by South Australian MP Rebekha Sharkie.
A new report shows lawyers are already managing the risks of unknowingly facilitating money laundering and don’t need to be subjected to “an extreme, disproportional and potentially damaging AML/CTF regime”, according to the Law Council of Australia.
Twenty-five barristers have joined the rank of silk in NSW, including one who represented AMP in a class action that settled for $100 million and another who is assisting the Commonwealth in its fight to recoup $325 million in excess subsidies in a dispute over generic Plavix.